{"id":"W2948352962","doi":"10.1182/bloodadvances.2018030387","title":"Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update","year":2019,"lang":"en","type":"review","venue":"Blood Advances","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":164,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University","funders":"Cilag; National Cancer Institute; Italfarmaco; Ipsen; Servier; Kyowa Hakko Kirin; Alexion Pharmaceuticals; Teva Pharmaceutical Industries; Daiichi Sankyo Europe; Sanofi; Biogen; Celgene; American Society of Clinical Oncology; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Biosimilar; Anemia; Randomized controlled trial; Internal medicine; Cancer; Intensive care medicine; Epoetin alfa; Guideline; Cochrane Library; Oncology; Myelodysplastic syndromes; Clinical trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007494678,0.0007984659,0.003545001,0.0001377565,0.0001090893,0.00002840288,0.0003091636,0.0003780898,0.0003465001],"category_scores_gemma":[0.0002720199,0.0005384833,0.0006746894,0.0005824608,0.0002348397,0.0002235346,0.0001891214,0.0006440967,0.00008772591],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002083503,"about_ca_system_score_gemma":0.0004853665,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000844205,"about_ca_topic_score_gemma":0.0000281609,"domain_scores_codex":[0.9948485,0.0002768546,0.002428418,0.001009978,0.0008772422,0.0005590178],"domain_scores_gemma":[0.9951929,0.0005806845,0.002662492,0.0008899123,0.0004645601,0.0002094508],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001331115,0.002247459,0.001124371,0.03973118,0.006181315,0.0009768184,0.00003023705,0.00004191543,1.923779e-7,0.00007941829,0.003318484,0.9461355],"study_design_scores_gemma":[0.003924587,0.00109573,0.00004984503,0.05780298,0.0299191,0.0001105169,0.0002598247,0.000007476061,0.000004446863,0.000005281153,0.9063381,0.0004821446],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001050892,0.9895404,0.00002811638,0.0006188178,0.0005302766,0.002079604,0.0001627439,0.0001210504,0.006813929],"genre_scores_gemma":[0.0000331592,0.950579,0.04528057,0.0003922802,0.0003351991,0.0001342615,0.0007668438,0.0001347357,0.002343937],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9456534,"threshold_uncertainty_score":0.9997067,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05770829144142951,"score_gpt":0.4484844334443418,"score_spread":0.3907761420029123,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}